Dilon Technologies, Inc. appears in FDA premarket approval records as the applicant for HEMOBLAST Bellows, an absorbable collagen hemostatic agent with thrombin. The supplied collection links two PMA records to the company, both with approval decisions, and both tied to P170012. The filings describe a device regulated as class 3 under product code PMX, with the advisory committee listed as General, Plastic Surgery. The original approval and a subsequent supplement give readers two dated reference points for how the product's regulatory record has been maintained. [1][2]

The documented product and its regulatory identity

HEMOBLAST Bellows is described in the FDA record as an absorbable collagen hemostatic agent with thrombin, carrying product code PMX and device class 3. The regulation number listed is 878.4490, and the advisory committee is recorded as General, Plastic Surgery. The applicant name on both linked records is Dilon Technologies, Inc. The FDA summary of safety and effectiveness data for P170012 lists the device generic name as hemostatic agent and the trade name as HEMOBLAST Bellows. [1][2][8]

The approved indication, as stated in the FDA record, covers use in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures. Dilon's product page describes HEMOBLAST Bellows as a hemostatic agent indicated for minimal, mild, and moderate bleeding and states that it contains human-derived thrombin. The page directs readers to the instructions for use for complete indications, contraindications, warnings, and precautions. [2][5]

Two dated approval records

The earliest linked record is the original P170012 approval, with a decision date of December 15, 2017, and a date received of March 30, 2017. The FDA summary of safety and effectiveness data for the same application records the date of FDA notice of approval as December 15, 2017, and states that CDRH issued an approval order that day. The record carries a Federal Register notice date of December 18, 2017. [2][8]

The second linked record is supplement P170012/S032, received June 29, 2026, and decided September 3, 2026. Its supplement reason is a location change affecting manufacturer, sterilizer, packager, or supplier, and the approval order statement describes an additional sterilization site located at Synergy Health Marseille, SAS (STERIS group), in Marseille, France. The supplement type is recorded as Normal 180 Day Track No User Fee, and the expedited review flag is N. [1]

Labeling and instructions for use

Dilon publishes instructions for use for HEMOBLAST Bellows. The document opens with a device description and sections covering indications for use, contraindications, warnings and precautions, directions for use, how supplied, storage, a summary of primary clinical studies, potential adverse events, and a symbols glossary. It carries a caution that federal law restricts the device to sale on or by the order of a physician, and it states that the device requires a prescription in the United States. [3][9]

The product page links to the instructions for use for HEMOBLAST Bellows and to a separate instructions document for a 35 cm nozzle extension. The page also notes that readers should contact Dilon Technologies or an authorized representative for details on product availability and status, and that the accompanying instructions should be consulted before use. [5]

How to read the supplied collection

MedtechLedger links two PMA records to the applicant name Dilon Technologies in the current FDA data: P170012 and P170012/S032. Both record approval decisions. The collection snapshot was retrieved on November 20, 2026. These two filings do not measure the company’s total sales, complete portfolio or safety performance. [1][2]

The FDA summary of safety and effectiveness data names Biom'Up SA, of Saint Priest, France, as the applicant's name and address on the original application, while the linked FDA records name Dilon Technologies, Inc. as applicant. The public documents do not establish a parent, brand, or ownership relationship between the two entities, and no headquarters location for Dilon Technologies, Inc. is documented here; the Virginia address in the FDA records is a filing address and is not treated as a headquarters. [1][2][8]